biote Corp. (NASDAQ:BTMD) Shares Sold by Sanders Morris Harris LLC

Sanders Morris Harris LLC trimmed its stake in shares of biote Corp. (NASDAQ:BTMD - Free Report) by 69.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 55,083 shares of the company's stock after selling 125,882 shares during the quarter. Sanders Morris Harris LLC owned approximately 0.10% of biote worth $330,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in BTMD. Barclays PLC lifted its stake in biote by 52.3% during the third quarter. Barclays PLC now owns 77,196 shares of the company's stock worth $432,000 after purchasing an additional 26,510 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of biote by 251.8% in the 2nd quarter. Renaissance Technologies LLC now owns 193,077 shares of the company's stock worth $1,442,000 after buying an additional 138,200 shares during the last quarter. State Street Corp lifted its position in shares of biote by 13.7% in the 3rd quarter. State Street Corp now owns 475,491 shares of the company's stock worth $2,653,000 after buying an additional 57,290 shares during the last quarter. Wasatch Advisors LP boosted its holdings in shares of biote by 8.4% in the 3rd quarter. Wasatch Advisors LP now owns 1,392,809 shares of the company's stock valued at $7,772,000 after buying an additional 107,792 shares during the period. Finally, Jane Street Group LLC grew its position in shares of biote by 24.7% during the 3rd quarter. Jane Street Group LLC now owns 16,873 shares of the company's stock valued at $94,000 after buying an additional 3,342 shares during the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

biote Stock Performance

Shares of biote stock traded down $0.30 during trading on Thursday, hitting $5.64. 89,822 shares of the stock were exchanged, compared to its average volume of 87,522. biote Corp. has a 12 month low of $3.65 and a 12 month high of $8.44. The stock's fifty day moving average is $6.17 and its 200 day moving average is $6.23. The stock has a market cap of $306.48 million, a PE ratio of 21.69 and a beta of 1.08.

Analyst Ratings Changes

Separately, Craig Hallum initiated coverage on shares of biote in a report on Monday, December 16th. They issued a "buy" rating and a $12.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $9.11.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.